|
Daily Medical Update
Antiphospholipid antibody syndrome
Wednesday, June 03, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Frontiers in immunology (2026) - Systematic Review and Network Meta-Analysis
Key Findings
- The 2023 ACR criteria had lower sensitivity than the 2006 revised criteria (relative sensitivity 0.80, 95% CI 0.72-0.89; P < 0.01) but higher specificity (relative specificity 1.06, 95% CI 1.05-1.08; P < 0.01).
- Network meta-analysis ranked the 2006 revised criteria highest for sensitivity (0.86, 95% CI 0.83-0.88), while the 2023 ACR/EULAR criteria had the highest specificity (0.98, 95% CI 0.97-0.98) and DOR (114.66, 95% CI 75.46-168.19).
📋 Practice Implication: Use the 2006 revised criteria when diagnostic sensitivity matters, and favor the 2023 ACR/EULAR criteria when higher-specificity classification is the priority.
|
Polish archives of internal medicine (2025) - Systematic Review and Meta-Analysis
Key Findings
- Thrombosis recurrence did not differ between DOACs and VKAs in single- or double-positive APS (RR 0.78, 95% CI 0.36-1.69).
- Major or clinically relevant nonmajor bleeding also did not differ between DOACs and VKAs (RR 0.78, 95% CI 0.30-2.05).
📋 Practice Implication: For non-triple-positive APS without clear arterial risk features, DOACs remain an individualized alternative when VKA management is difficult.
|
Seminars in arthritis and rheumatism (2025) - Systematic Review and Meta-Analysis
Key Findings
- Across 1307 APS patients, DOACs increased the composite thrombotic endpoint versus VKAs (IRR 2.33, 95% CI 1.18-4.58), driven by arterial events (IRR 2.70, 95% CI 1.42-5.13).
- DOACs were linked to more myocardial infarction (IRR 4.71, 95% CI 1.00-22.21) and stroke (IRR 7.48, 95% CI 1.27-44.13), while VTE and bleeding rates did not differ significantly.
📋 Practice Implication: For established thrombotic APS, VKAs should remain the default anticoagulant because pooled evidence shows excess arterial events with DOACs.
|
RMD open (2025) - Systematic Review and Meta-Analysis
Key Findings
- Live births were higher with HCQ plus standard therapy than with standard therapy alone (89.9% vs 73.9%; OR 2.66, 95% CI 1.44-4.91).
- Obstetric complications were lower with HCQ (19.3% vs 55.0%; OR 0.19, 95% CI 0.19-0.39), and treatment was well tolerated.
📋 Practice Implication: In obstetric APS with persistent risk despite aspirin and heparin, adding hydroxychloroquine deserves consideration during maternal-fetal treatment planning.
|
Frontiers in immunology (2026) - Systematic Review and Meta-Analysis
Key Findings
- In SLE, aPL positivity was associated with higher renal injury risk than aPL negativity (OR 2.09, 95% CI 1.70-2.58).
- Renal injury risk was increased with lupus anticoagulant (OR 2.43, 95% CI 1.64-3.61), anticardiolipin antibodies (OR 1.71, 95% CI 1.34-2.18), and antiphospholipid syndrome (OR 2.07, 95% CI 1.48-2.89).
📋 Practice Implication: aPL-positive SLE patients warrant closer renal surveillance, especially when lupus anticoagulant or anticardiolipin antibodies are present.
|
|
💡
Summary
Recent APS evidence is clustering around diagnosis, anticoagulant selection, and pregnancy management. A 2026 network meta-analysis suggests the 2006 revised Sapporo criteria remain the most sensitive framework while the 2023 ACR/EULAR criteria are the most specific, and anticoagulation data continue to favor vitamin K antagonists over DOACs for thrombotic APS overall because arterial events are higher with DOACs. Pregnancy-focused data support adjunctive hydroxychloroquine with standard therapy, and broader antibody data in SLE reinforce closer renal surveillance when APS-spectrum antibodies are present.
|
|